Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial

Fig. 2

Tumor responses of 36 patients in the per-protocol set. A The waterfall plot shows the best percentage changes in target lesions from baseline according to Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1. B The spider plot displays longitudinal changes from baseline in tumor size. The dotted lines at − 30% and 20% indicate partial response (PR) and progression per RECIST, respectively. C Treatment exposure and response duration. D Radiographic response by serial CT scans in pulmonary (upper panel) and hepatic (lower panel) metastases in nasopharyngeal carcinoma patients

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us